David P. Meeker, M.D. is President of the LSD (Lysosomal Storage Diseases) Therapeutics business unit of Genzyme Corporation. During his leadership of the LSD business unit, Dr. Meeker has held development responsibility for its therapeutics portfolio, and global responsibility for three marketed enzyme replacement products which have generated over one billion dollars in revenue.
In addition to serving as President of the LSD unit, Dr. Meeker has served in various roles at Genzyme Corporation since joining in 1994, including Senior Vice President, Therapeutics Europe and Senior Vice President, Medical Affairs. Dr. Meeker has had extensive experience in the development and market launch of orphan drugs while at Genzyme. Prior to joining Genzyme, he served at the Cleveland Clinic Foundation, initially joining in 1988 as Staff Physician for the Department of Pulmonary and Critical Care Medicine and later serving as the Program Director for the Department's fellowship program.
Dr. Meeker is a Fellow at the American College of Physicians (FACP) and the American College of Chest Physicians (FCCP), and has published over 50 articles in academic journals and research publications. He attended Dartmouth College and holds a M.D. from The University of Vermont. His post- doctoral training included a Fellowship in Pulmonary Medicine at Boston University, a Clinical Fellowship in Medicine at Harvard Medical School and Residency in Internal Medicine at Beth Israel Hospital Boston.